Making Medicine Incubate Coalition

How can we create better outcomes for cancer patients?

That’s the big goal Mohit Manrao is aiming for in his work as SVP & Head of US Oncology at AstraZeneca. In this episode, Mohit shares his perspective on the future of oncology and the pursuit of patient-centric care in a post-Inflation Reduction Act world.

Join us as we discuss:
AstraZeneca's goal of launching 15 new drugs by 2030Solving for disparities in care and improving health equityTimeline for drug development and its effect on patient outcomes

Can we create a future healthcare system that is accessible and affordable for all patients?

That’s the major question that Mary R. Grealy, CEO of Healthcare Leadership Council, is trying to answer through her work. Mary, a former speech pathologist turned lawyer, shares insights from her unique journey from the healthcare field to advocating for patient-centered, value-based healthcare systems. In this wide-ranging conversation, Mary shares the challenges faced in the industry but also her hope for a future where patients are empowered through collaboration and innovation.

Join us as we discuss:
Why collaboration between stakeholders is keyPractical tips for advocates to make a compelling case to CongressThe potential effects of the new price-setting systemThe impact of proposed legislation on treatments and cures

With recent movement in healthcare including President Biden’s Cancer Moonshot and the Inflation Reduction Act, one thing is clear: American healthcare is at a crossroads.

As we begin to tackle the conversation of healthcare reform, how can we rebuild the system around patients?

In this episode, MacKay Jimeson, Executive Director of The Patient Access & Affordability Project at Patients Rising, joins the show to explain how the system was never designed for patients, the benefits of a patient-centric system, and what the future holds for the industry.

Join us as we discuss:
Why patient-centricity is notably absent in our healthcare systemMacKay’s op-ed in response to President Biden’s SOTUThe impact of The Inflation Reduction Act and Centers for Medicare & Medicaid Services on today’s healthcare landscapeThe true human impact of medicines

MacKay’s Op-Ed: https://www.statnews.com/2023/02/09/state-of-the-union-highlights-americas-awkward-conversation-on-science-medicine-and-financing-the-development-of-new-medicines/

MacKay’s Bio:
https://accessandaffordability.org/person/02-mackay-jimeson/

Even though 80% of the household decisions around health are made by women, only 4% of research and funding goes towards women’s health research.

In today’s episode, Natalie Buford-Young, Chief Executive Officer at Springboard Enterprises, joins us to discuss Springboard’s mission and how they are exploring a designated network to create pathways for emerging female innovators.

We also get to hear about Natalie's experience testifying on the Hill to advocate for reducing the decline of women's entrepreneurship.

Join us as we discuss:
· Innovation in digital health and life sciences;
· The Women's Health Innovation Coalition; and
· Increasing diversity in clinical trials.

Runaway inflation and economic instability is terrible for just about everybody, but are efforts to tackle this problem creating more?
To answer that, Kirsten Axelsen, Senior Policy Advisor at DLA Piper, joins the show to break down all the effects The Inflation Reduction act is having upon medicine,
We discuss:The potential negative impacts on small-molecule medicineHow the act affects patents and generic medicineWhy we may see declines in small-molecule medicine research

John was at the JP Morgan conference and is here to discuss the key takeaways of the Inflation Reduction Act: the small-molecule penalty, the value of small-molecule drugs, the importance of incentivizing post-approval research, intellectual property, and non-coverage decisions at CMS. You’ll also hear John’s take on the demand for a more pro-patient agenda. There was a lot of focus on the role of policy and government, specifically in relation to the inflation reduction act and its impact on the life science and venture capital industries.

Ready to reaffirm its values, Incubate will be focusing its energy on working with the White House and Congress to make necessary amendments to the legislation. They’ll also have a focus on education and awareness to ensure that policymakers understand the critical role they play in the healthcare landscape.

Join us as we discuss:Why is there excitement for 2023 in the biotech sector, but also some anxiety?How does the organization, Incubate, plan to address the inflation reduction act?What Congress can be doing to create a more pro-patient agenda?